JHL Biotech is extremely humbled and couldn’t be more proud to receive the 2020 Bioprocessing Excellence in Downstream Processing Award in the Greater China Region as part of IMAPAC’s Asia-Pacific Bioprocessing Excellence Awards. It is a great feeling to be recognized for such a prestigious award and we will continue to strive towards our mission of making medicines affordable and available to all patients who are in need of these life-saving therapies.
The Awards Ceremony was held in association with the 7th Biologics Manufacturing Asia and 4th Biologics World Asia Virtual Conference 7th and 8th of July, 2020.
About JHL Biotech
JHL Biotech, Inc. is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, VMS Investment Group, and the China Development Industrial Bank. JHL Biotech’s mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on continuing to provide the highest-quality CDMO services for our esteemed clients and also research and development of new protein-based therapies and biosimilars. JHL has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards and can produce biological products to be marketed globally. For more information, please visit www.jhlbiotech.com.